Total Voting Rights

RNS Number : 7786B

AstraZeneca PLC

03 February 2020

 

03 February 2020 15:00 GMT

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 January 2020 the issued share capital of AstraZeneca PLC with voting rights is 1,312,187,447 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,312,187,447.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Media Relations
Gonzalo Viña		[phone]
Rob Skelding	Oncology	[phone]
Rebecca Einhorn	Oncology	[phone]
Matt Kent	BioPharmaceuticals	[phone]
Angela Fiorin	BioPharmaceuticals	[phone]
Jennifer Hursit	Other	[phone]
Christina Malmberg Hägerstrand	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Henry Wheeler	Oncology	[phone]
Christer Gruvris	BioPharmaceuticals (Cardiovascular, Metabolism)	[phone]
Nick Stone	BioPharmaceuticals (Renal) Environmental, Social and Governance	[phone]
Josie Afolabi	BioPharmaceuticals (Respiratory)	[phone]
Tom Waldron	Other medicines	[phone]
Craig Marks	Finance Fixed income	[phone]
Jennifer Kretzmann	Corporate access Retail investors	[phone]
US toll-free		[phone]

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END

 

 

TVRFLFEFFSIVIII